RAISING THE QUALITY STANDARD
Legacy Cancer Institute delivers exceptional breast cancer care.
Meet our providers
How our program compares
Our breast cancer program is among the top in the nation when measured by our quality of care. We not only exceed our peers in the region, but we also are better than national averages in terms of providing recognized standards of cancer care. Our performance in these accreditation programs tells you that we provide the highest level of care cancer available.
The numbers tell the story
Through a review process from independent groups, the quality of our breast cancer program is measured against standards developed by national experts. The results show how often Legacy Cancer Institute exceeds our peers in reaching the ultimate target goal of 100 percent.
Radiation therapy after mastectomy with positive lymph nodes –– among top 5% nationally
Pacific Northwest: 86.7%
Quality measure detail: Radiation therapy is recommended or administered following any mastectomy within one year of diagnosis of breast cancer for women with at least 4 positive regional lymph nodes.
Radiation therapy after breast conserving surgery
Pacific Northwest: 90.7%
Quality measure details: Radiation therapy is administered within one year of diagnosis for women under age 70 receiving breast-conserving surgery for breast cancer.
Chemotherapy for hormone receptor negative breast cancer –– among the top 5% nationallyLegacy: 100%
Pacific Northwest: 91.3%
Quality measure details: Combination chemotherapy is recommended or administered within four months of diagnosis for women under age 70 with AJCC T1cN0M0 or Stage IB - III hormone receptor negative breast cancer.
Needle biopsy to establish breast cancer diagnosis –– among the top 5% nationally
Pacific Northwest: 93%
Quality measure details: Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.
Hormonal therapy for hormone receptor positive breast cancer -–– among the top 5% nationally
Pacific Northwest: 92.5%
Quality measure details: Tamoxifen or third generation aromatase inhibitor is recommended or administered within one year of diagnosis for women with AJCC T1cN0M0 or Stage IB - Stage III hormone receptor positive breast cancer.
The most recent American College of Surgeons Commission on Cancer quality indicators, showing how Legacy ranks against our peers. Table shows the proportion of breast cancer patients treated according to nationally recognized standards of care. Data is the most recent available, 2015.
You are not alone. Legacy offers support throughout your cancer journey, as well as care for your emotional, social and spiritual needs.